Recent News

• 04.25.2025 - Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
• 04.25.2025 - Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
• 04.07.2025 - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
• 04.07.2025 - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
• 03.27.2025 - Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
• 03.27.2025 - Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
• 03.25.2025 - Virtual Corporate R&D Event
• 03.25.2025 - Virtual Corporate R&D Event

Recent Filings

• 04.21.2025 - 3 Initial statement of beneficial ownership of securities
• 04.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.07.2025 - 8-K Current report
• 04.07.2025 - EX-99.1 EX-99.1
• 04.03.2025 - 3 Initial statement of beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.27.2025 - 8-K Current report
• 03.27.2025 - EX-99.1 EX-99.1